FDA says ‘no’ to serelaxin for heart failure

The FDA followed the lead of its counterpart in Europe by rejecting a bid from Novartis to approve serelaxin as a treatment for acute heart failure. The FDA stated that it needed more proof of the drug’s efficacy.

The FDA granted serelaxin breakthrough therapy designation in June 2013. Novartis proposed it as a symptom reliever for patients with acute heart failure who present at the emergency department. Serelaxin, a vasoactive peptide hormone, was to be infused over a 48-hour period to help relax blood vessels and reduce fluid buildup.

In the international placebo-controlled randomized Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial, serelaxin was found to provide dyspnea relief in patients with acute heart failure who had been admitted to a hospital but treatment had no effect on hospital readmission. Earlier this year, the Committee for Medicinal Products for Human Use in Europe determined that serelaxin failed to provide short-term relief but that it did show benefits over five days.

The committee questioned the clinical relevance of that benefit, though, and did not support serelaxin’s approval. The FDA’s Cardiovascular and Renal Drugs Advisory Committee, in a meeting in March, also voted unanimously against approval of the drug.

Basel-based Novartis said it will continue to its efforts with the ongoing RELAX-AHF-2, which will enroll almost three times as many patients.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup